This CE activity was originally published in The Rx Consultant. If you received credit for it previously, you cannot receive credit for it again.Hypertension is the most common chronic condition seen by primary care providers, affecting 1 out of 3 adults in the United States. In many communities, fewer than half of people with hypertension have their blood pressure (BP) adequately controlled. Hypertension increases the risk of cardiovascular events, stroke, and kidney disease. Epidemiological studies have shown that these risks begin to rise as BP increases above 115/75 mm Hg – ie, starting at levels below those defined as hypertension or even pre-hypertension (Table 1). For every increase of 20/10 mm Hg, the risk of major cardiovascular events, including stroke, approximately doubles.
This issue of The Rx Consultant focuses on selected controversies and recent developments in the management of primary (essential) hypertension in adults. These include a new US guideline with new recommendations for when to start treatment; recommended options for initial antihypertensive drug therapy; hypertension management in black people; and an ongoing controversy about dietary sodium. It is important for all providers, including pharmacists, to be up to date on these developments; a team approach may help more patients achieve their BP goals. For background information about hypertension, see the July/August 2010 issue of The Rx Consultant.
This issue of The Rx Consultant focuses on selected controversies and recent developments in the management of primary (essential) hypertension in adults. These include a new US guideline with new recommendations for when to start treatment; recommended options for initial antihypertensive drug therapy; hypertension management in black people; and an ongoing controversy about dietary sodium. It is important for all providers, including pharmacists, to be up to date on these developments; a team approach may help more patients achieve their BP goals. For background information about hypertension, see the July/August 2010 issue of The Rx Consultant.
Format
This CE activity is a monograph (PDF file).
Fee
$10.00
CE Hours
1.50
CE Units
0.150
Activity Type
- Knowledge-based
Target Audience(s)
- This accredited program is targeted to pharmacy technicians.
Accreditation(s)
This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.
CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours. CE credit is automatically reported to CPE Monitor.
CE activities for Nurse Practitioners and Clinical Nurse Specialists:
This continuing education activity meets the requirements of:
The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
This is a pharmacotherapeutics/pharmacology CE activity.
- The ANCC requires all advanced practice nursing certificants (CNSs and NPs) to complete 25 CE hours of pharmacotherapeutics as a portion of the required 75 continuing education hours.
- Pharmacology CE is recommended by the AANPCP and will be required for Certificants renewing certification starting January 2017.
- Most State Boards of Nursing require a minimum number of pharmacy contact hours to renew an advanced practice license.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Requirements for CE Credit
CE for this article is no longer valid.
Objectives
- State the blood pressure goals recommended by the current Joint National Committee (JNC8) guideline. Name the 4 drug classes recommended by JNC8 for initial antihypertensive therapy.
- Give examples (brand and generic names) of each of the following drug classes: ACE inhibitors, ARBs, ?-blockers, calcium channel blockers, and thiazide-type diuretics.
- State the American Heart Association and United States federal recommendations for dietary sodium intake.
Speaker(s)/Author(s)
|
Heather C. Ulrich, PharmD, BCPS, CDE Brief Bio : Heather C. Ulrich, PharmD, BCPS, CDE, Clinical Pharmacist, Lebanon VA Medical Center, Lebanon, PA. Disclosure : Dr. Ulrich reports no financial or personal relationship with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue. |
|
|
Pamela Mausner, MD Brief Bio : Pamela Mausner, MD; Medical Writer/Editor and Healthcare Advocate; and Associate Editor, The Rx Consultant. Disclosure : Dr.Mausner reports no financial relationship with the manufacturer(s) or provider(s) of any commercial product(s) or service(s) that appear in this issue. |
|
|
Tracy Farnen, PharmD Brief Bio : Tracy Farnen, PharmD; Managing Editor, The Rx Consultant. Disclosure : Dr. Farnen reports no financial relationship with the manufacturer(s) or provider(s) of any commercial product(s) or service(s) that appear in this issue. |
Activity Number
0428-0000-14-012-H01-T
Release Date:
Aug 25, 2014
Credit Expiration Date:
Aug 25, 2017
CE Hours
1.50
Fee
$10.00